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Lewis Taylor1, David R. Greaves1‡ and Asif J. Iqbal1,2*‡
1 Sir William Dunn School of Pathology, University of Oxford, Oxford, United Kingdom, 2 College of Medical and Dental 
Sciences, Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, United Kingdom
Chemerin is a chemotactic protein that induces migration of several immune cells 
including macrophages, immature dendritic cells, and NK  cells. Chemerin binds to 
three G protein-coupled receptors (GPCRs), including CCRL2. The exact function of 
CCRL2 remains unclear. CCRL2 expression is rapidly upregulated during inflammation, 
but it lacks the intracellular DRYLAIV motif required for classical GPCR downstream 
signalling pathways, and it has not been reported to internalise chemerin upon binding. 
The aim of this study was to investigate what role if any CCRL2 plays during acute 
inflammation. Using the zymosan- and thioglycollate-induced murine models of acute 
inflammation, we report that mice deficient in the Ccrl2 gene display exaggerated local 
and systemic inflammatory responses, characterised by increased myeloid cell recruit-
ment. This amplified myeloid cell recruitment was associated with increased chemerin 
and CXCL1 levels. Furthermore, we report that the inflammatory phenotype observed 
in these mice is dependent upon elevated levels of endogenous chemerin. Antibody 
neutralisation of chemerin activity in Ccrl2−/− mice abrogated the amplified inflamma-
tory responses. Importantly, chemerin did not directly recruit myeloid cells but rather 
increased the production of other chemotactic proteins such as CXCL1. Administration 
of recombinant chemerin to wild-type mice before inflammatory challenge recapitulated 
the increased myeloid cell recruitment and inflammatory mediator production observed 
in Ccrl2−/− mice. We have demonstrated that the absence of CCRL2 results in increased 
levels of local and systemic chemerin levels and exacerbated inflammatory responses 
during acute inflammatory challenge. These results further highlight the importance of 
chemerin as a therapeutic target in inflammatory diseases.
Keywords: ccrl2, chemerin, g protein-coupled receptor, inflammation, chemokines, neutrophils
inTrODUcTiOn
Understanding the endogenous pathways that regulate inflammatory responses is of critical impor-
tance for the development of novel therapies for chronic inflammatory disease. Recent approaches 
for the treatment of inflammatory diseases have focussed around blocking specific inflammatory 
mediators such as the cytokines TNF-α, IL-1β, and IL-6 (1–3). Whilst such approaches have been 
very effective for certain diseases [e.g., anti-TNF-α monoclonal antibodies for the treatment of 
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rheumatoid arthritis (RA)] a large percentage of patients either 
do not respond to treatment or become refractory to therapeutic 
antibody treatment (4, 5). It is known that cytokines play a cen-
tral role in shaping the immune response to invading pathogens 
and in the context of chronic inflammation. It is now appreciated 
that there exists a plethora of lipid mediators as well as other 
immune modulating proteins and peptides that play important 
roles during both the onset as well as the resolution of inflam-
mation (6–8). Annexin-A1 and its N-terminal peptide ac2-26 
have been demonstrated to exert potent pro-resolution proper-
ties in multiple inflammatory disease models (8, 9). Similarly, 
a number of lipid mediators including the resolvins, lipoxins, 
maresins, and protectins have been more recently come to the 
fore (7, 8). These novel immune modulatory mediators and oth-
ers may represent new avenues to explore for the treatment of 
chronic inflammatory disease.
Murine chemerin is a 16 kDa protein produced and secreted 
as an inactive precursor, pro-chemerin, predominantly by 
hepatocytes and adipocytes (10). Pro-chemerin is present in the 
liver, spleen, skin, and plasma (11, 12). During an inflammatory 
response, inflammatory proteases produced locally by granulo-
cytes and the coagulation cascade, cleave the carboxyl terminus 
of pro-chemerin to generate active chemerin isoforms at sites 
of inflammation (13, 14). Chemerin has been implicated in the 
pathology of a range of inflammatory diseases including RA, 
inflammatory bowel disease, psoriasis, diabetes, and cardiovas-
cular disease (15–19). However, the exact role played by chemerin 
and its receptors in inflammatory disease remains unclear.
Our group and others have demonstrated that active 
chemerin, once generated, is a potent chemoattractant for 
macrophages, immature dendritic cells (DCs), plasmacytoid 
dendritic cells (pDCs), and NK cells (20–23). Chemerin binds to 
three G protein-coupled receptors (GPCRs) with high affinity; 
CMKLR1, GPR1, and CCRL2 (24). Murine GPR1 is expressed 
in white adipose tissue, skin, muscle, and in the central nervous 
system (25). Although chemerin binding to GPR1 has been 
reported to induce downstream signalling, chemerin is thought 
to act as a partial agonist at GPR1 whilst chemerin acts as a 
full agonist at CMKLR1 (26, 27). CMKLR1 is expressed on 
various immune cells including macrophages, DCs, NK  cells, 
and pDCs (12). It is also expressed on endothelial cells and 
adipocytes (28, 29). Cmklr1 mediates the chemotactic effects of 
chemerin, and its activation has been reported to lead to rapid 
downstream signalling cascades, which are Gi/0 coupled (23, 
26). The Chemerin/Cmklr1 axis has been implicated in driving 
the recruitment of immature DCs, pDCs, and NK cells to local 
sites of inflammation in a number of inflammatory diseases (22, 
30–32). Interestingly, Cmklr1 has also been reported to play an 
anti-inflammatory role in a number of inflammatory disease 
models, although these have predominantly been allergic 
inflammatory models (12, 33). In addition, our group and others 
have reported anti-inflammatory effects of synthetic chemerin-
derived peptides in a number of inflammation models and these 
effects seem to be dependent on CMKLR1 (34–36).
CCRL2 is a seven transmembrane receptor that lacks the 
DRYLAIV intracellular motif required for classical downstream 
signalling by GPCRs (37). It binds chemerin but does not induce 
classical downstream signalling nor does it internalise chemerin 
(20, 37, 38). CCRL2 is expressed on a range of cell types includ-
ing macrophages, DCs, endothelial cells, and epithelial cells 
amongst others (38, 39). Expression of CCRL2 is upregulated 
in response to inflammatory stimuli but the function of CCRL2 
during inflammation remains incompletely understood (39, 40). 
Zabel et al. have proposed a model in which CCRL2 binds to the 
non-signalling N-terminus of chemerin and then presents it to 
other cells expressing CMKLR1. In this way, CCRL2 could func-
tion to concentrate chemerin at local sites to augment chemerin 
signalling during inflammation (38). The aim of this study was to 
further explore the role of the non-signalling chemerin receptor 
CCRL2 during a self-resolving model of acute inflammation.
We report, for the first time, that animals lacking the chemerin 
receptor CCRL2 displayed exaggerated neutrophil and inflam-
matory monocyte recruitment in models of acute inflammation. 
These effects were due in part to increased levels of chemerin, 
which augmented production of the neutrophil chemoattractant 
CXCL1, resulting in increased neutrophil recruitment.
MaTerials anD MeThODs
animals
B6.129-Ccrl2tm1Dgen/J mice were obtained from Jackson 
Laboratories (Bar Harbour, ME, USA). These mice, originally 
produced by Deltagen (San Mateo, CA, USA), were backcrossed 
for 12 generations onto the C57BL/6J background. All animal 
studies were conducted with ethical approval from the Dunn 
School of Pathology Local Ethical Review Committee and in 
accordance with the UK Home Office regulations (Guidance on 
the Operation of Animals, Scientific Procedures Act, 1986).
reagents
Recombinant murine chemerin (aa17–156) was reconstituted in 
PBS supplemented with 0.1% BSA. Neutralising anti-chemerin 
antibody and goat IgG control were reconstituted in PBS. Both 
chemerin and antibodies were purchased from R&D Systems 
(Abingdon, UK). Zymosan was purchased from Sigma-Aldrich 
(Dorset, UK). Recombinant CCL5 was purchased from Peprotech 
(London, UK). Bio-gel P100 (45–90  µm) fine polyacrylamide 
beads were obtained from BIO-RAD Laboratories, Hemel 
Hempstead, Hertfordshire, UK.
Murine Bone Marrow-Derived 
Macrophages (BMDMs)
Bone marrow-derived macrophages were generated as previously 
described (41). Briefly, fresh bone marrow cells from tibiae and 
femurs of C57BL/6J mice (8–12  weeks) were isolated and cul-
tured in DMEM media supplemented with 10% heat inactivated 
fetal bovine serum, 10% L929 cell-conditioned media as a source 
of macrophage colony-stimulating factor, 100  U/ml penicillin, 
and 100 µg/ml streptomycin for 7 days. A total of 4 × 106 bone 
marrow cells were seeded into 10 ml of medium in 100 mm Petri 
dishes (Sterilin, Abergoed, UK.) and on day 3 an additional 5 ml 
of medium was added. Cells were harvested by gentle agitation 
to lift cells off surface.
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human Umbilical Vein endothelial cells 
(hUVec)
Human umbilical vein endothelial cells were isolated as previ-
ously described (42) and frozen for storage in liquid N2. HUVEC 
were thawed and resuspended in endothelial cell growth medium 
with supplement mix C (PromoCell, Germany), 100 U/ml peni-
cillin, and 100  µg/ml streptomycin and cultured in pre-coated 
0.5% gelatin (Sigma) flask/dishes in a 37°C 5% CO2 incubator.
cell activation assays
Cells were seeded into 6-well plates at a concentration of 1 × 106/ml. 
They were then exposed to TLR ligands and cytokines for 16 h in a 
37°C 5% CO2 incubator as described previously. The TLR ligands 
and cytokines were added to cells at a final concentration of: LPS 
100 µg/ml, IFNγ 20 ng/ml, Poly I:C 10 µg/ml, zymosan 10 µg/ml, 
flagellin 500 ng/ml, IL-4 20 ng/ml, and IL-13 20 ng/ml.
rna isolation and reverse Transcription 
and rT-Pcr
Total RNA was extracted using the QIAGEN RNeasy Mini kit 
as instructed by the manufacturer as described previously (43). 
RNA concentration and purity was determined using ND-1000 
spectrophotometer (Nanodrop, Thermo Scientific) at 260/280 
and 260/230 nm. cDNA was synthesised from 500 to 800 ng of 
total RNA using QuantiTect Reverse Transcription kit following 
the manufacturer’s instructions. cDNA was amplified for 15 min 
at 42°C and then 3 min at 95°C. Real-time quantitative PCR was 
performed using Sybr Select Master Mix (Applied Biosystems, 
Life Technologies) in the Step One Plus Real-time PCR System 
(Applied Biosystems). All primers were from QuantiTect Primer 
Assay (Qiagen). The thermal profile included an initiation step 
for 2 min at 50 and 95°C followed by 40× cycles of 15 s at 95°C 
and 1 min at 60°C. Cycle threshold values were determined by 
the StepOne software v2.3 and the mRNA content of samples 
was inferred by normalising to the housekeeping β-actin gene. 
Relative expression results were plotted as mRNA expression over 
actin, normalised to basal samples (44).
Zymosan or Thioglycollate induced 
Peritonitis
Male Ccrl2−/− or littermate controls were injected i.p. (0.5  ml) 
with 100 µg zymosan resuspended in PBS, or 1 ml of 4% thio-
glycollate (Thioglycollate brewers yeast; Sigma-Aldrich, Dorset, 
UK) prepared as described previously (45). Mice were sacrificed 
at specified time points and peritoneal cavities were lavaged with 
5 ml ice-cold PBS supplemented with 2 mM EDTA. Blood was 
collected from the hepatic portal vein into EDTA-coated vacu-
tainers and centrifuged at 2,000 × g for 20 min at 4°C to obtain 
plasma.
Modulation of chemerin levels In Vivo
C57BL/6J mice were treated with either recombinant murine 
chemerin (4 µg) or PBS i.p. for 1 h before zymosan challenge for 
4 h. Animals were sacrificed and peritoneal lavage was collected 
as before. Ccrl2−/− mice were pretreated for 24  h with either 
100 ng of isotype control IgG antibody or 100 ng of anti-chemerin 
polyclonal antibody i.p. This was followed by a second injection 
of isotype control IgG or anti-chemerin antibody 1 h before chal-
lenge with zymosan. Mice were sacrificed 4 h later and peritoneal 
lavage fluid was collected as before.
Flow cytometry
Peritoneal exudate cells (PECs) were resuspended in 
fluorescence-activated cell sorting (FACS) buffer (PBS; 2% 
FCS, 25  mM HEPES, 5  mM EDTA) containing CD16/CD32 
FCγIIR blocking antibody (eBioscience). Specific staining 
with the following antibodies was performed with appropriate 
isotype controls; F4/80 (AbD Serotec, clone CI:A3-1), Ly6B.2 
(AbDSerotec, Clone 7/4), Ly6 G (BioLegend, clone 1A8), 
CD11b (BioLegend, clone M1/70), CD115 (BioLegend, clone 
AFS98), CD4 (BioLegend, clone RM4-5), CD3 (BioLegend, 
clone 17A2), B220 (eBioscience, clone RA3-6B2), CD8 (BD 
Pharminogen, clone 53-6.7), and analysed by flow cytometry. 
Cells were counted using CountBright Absolute Counting Beads 
(Life Technologies). Cells were analysed with a Dako Cyan ADP 
flow cytometer (Beckman Coulter Ltd., High Wycombe, UK) 
and FlowJo software V10 (Tree Star Incorporation, Ashland, 
OR, USA). Monocytes and neutrophils in the peritoneum 
were defined as CD45+, 7/4+, Ly6G− and CD45+, 7/4+, Ly6G+, 
respectively (46, 47). Blood was collected via hepatic portal 
vein into EDTA-coated vacutainers. Blood was treated in the 
same manner as the PECs, but red blood cells were lysed after 
antibody staining using BD FACS Lysing Solution (Buffered 
solution with <15% formaldehyde and <50% diethylene glycol) 
before fixation. Ly6Chi blood monocytes were defined as CD45+, 
CD11b+, CD115+, Ly6Chi. Ly6Clo monocytes were defined as 
CD45+, CD11b+, CD115+, Ly6Clo (48, 49).
Fluorescence-activated cell sorting
Male C57BL/6J mice were injected i.p. (0.5  ml) with 100  µg 
zymosan resuspended in PBS. Steady state and zymosan chal-
lenged mice were sacrificed 4 h later, and peritoneal cavities were 
lavaged with 5 ml ice-cold PBS supplemented with 2 mM EDTA. 
PECs were stained for flow cytometry as described previously. 
Peritoneal macrophages, monocytes, and neutrophils were FACS 
sorted using a Beckman Astrios cell sorter directly into RLT 
buffer for RNA isolation using the QIAGEN RNeasy Mini kit.
Detection of secreted Protein by elisa 
and luminex
CXCL1, CCL2, IL-6, and chemerin in peritoneal exudate fluid 
and plasma were detected using ELISA (R&D Systems, Abingdon, 
UK). Sandwich ELISAs for chemerin, IL-6, CCL2, and CXCL1 
were performed according to manufacturer’s instructions. 
Custom multiplex polyacrylamide bead assays were purchased 
from R&D Systems to determine levels of CCL3, CCL4, IL-10, 
CXCL10, and MMP9 in peritoneal exudate fluid. Briefly, colour-
coded beads were pre-coated with antibodies against the targets 
of interest. Biotinylated detection antibodies specific for each 
analyte were added, followed by phycoerythrin (PE)-conjugated 
streptavidin. Samples were read using a laser detection system, 
which quantifies the amount of PE present for each analyte. The 
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96-well plates were read on a Bio-Rad Bioanalyser with Bio-Plex 
Manager software (Hemel Hempstead, Hertfordshire, UK).
acea xcelligence chemotaxis assay
8- to 10-week-old male Ccrl2−/− or littermate controls were 
injected i.p. with 1 ml 2% Bio-gel (P100 Fine, 45–90 µm). PECs 
(mixture of inflammatory macrophages and neutrophils) were 
isolated by peritoneal lavage with ice-cold PBS supplemented 
with 2 mM EDTA 4 days later. Real-time chemotaxis assays were 
performed using the ACEA RTCA-DP instrument as described 
previously (50, 51). Briefly, vehicle, chemerin, or recombinant 
murine CCL5 (160 µl) at 5 nM final concentration was added to 
the lower chamber of a CIM-16 plate. The upper chamber was 
attached, and 50  µl of prewarmed chemotaxis buffer added to 
each of the upper chambers. Following equilibration for 30 min, 
the plate was transferred into the RTCA-DP system. Bio-gel elic-
ited PECs (50 µl—4 × 105 cells/well), were then added to all upper 
wells. Cell index (CI) measurements were then taken every 5 s 
over the 3–4 h assay period. Chemotactic responses were assessed 
by quantifying the slope of the curve in the first 40 min and by the 
maximum CI minus minimum CI (Max–Min) values of the curve 
over the entire experiment.
cMKlr1 β-arrestin recruitment assays
Recruitment of β-Arrestin to CMKLR1 was measured using the 
Discoverx PathHunter® eXpress β-Arrestin GPCR Assay follow-
ing the manufacturer’s protocol. Briefly, CHO-K1 cells stably 
expressing murine CMKLR1 were seeded into 1/2 area 96-well 
plates (15,000 cells/well) and incubated at 37°C, 5% CO2 for 48 h. 
Cells were then treated with either vehicle (Cell assay reagent) or 
indicated concentrations of anti-chemerin antibody for 45 min 
at 37°C, 5% CO2 before stimulation with vehicle or recombinant 
chemerin (20 nM) for 90 min at 37°C, 5% CO2. Cells were lysed 
and detection of total recruited β-arrestin was determined follow-
ing the manufacturers protocol and as previously described (51). 
Luminescence measurements were taken using a PHERAstar 
microplate reader (BMG Labtech).
statistical analysis
All quantitative data are reported as mean ± SEM of n independ-
ent biological replicates. Statistical significance was assessed 
using a Student’s unpaired t-test, one-way or two-way analysis of 
variance (ANOVA) with Dunnett’s multiple comparison post hoc 
test (Prism 6 GraphPad Software, San Diego, CA, USA), P < 0.05 
was taken to be statistically significant.
resUlTs
chemerin levels and Ccrl2 expression are 
increased during acute inflammation
We and others have previously demonstrated that i.p. challenge 
with zymosan induces robust inflammatory mediator produc-
tion in the peritoneum as well as inflammatory cell recruitment 
(47). Injection of 100  µg zymosan resulted in robust inflam-
matory cell recruitment with neutrophils peaking at 4 h post 
zymosan challenge and monocytes peaking at 8 h (Figure 1A). 
The role played by chemerin during inflammation remains 
incompletely understood. To interrogate this in our model 
of acute inflammation, we quantified total chemerin levels in 
the peritoneum during this acute inflammatory response and 
found that levels were significantly increased compared with 
naïve mice 4 h following zymosan challenge (2.5 ± 0.4 ng/ml at 
4 h compared with 1.2 ± 0.3 ng/ml in naïve mice) (Figure 1B). 
One caveat using an ELISA to measure chemerin levels is that 
it is a quantification of total chemerin levels, including inactive 
pro-chemerin and potentially shorter bioactive chemerin iso-
forms generated during inflammation. To investigate chemerin 
bioactivity during this acute inflammatory response, we com-
pared the ability of the peritoneal exudate fluid from animals 
injected with zymosan at different time points to activate the 
CMKLR1 chemerin receptor on CMKLR1 transfected CHO-
K1 cells (Figure 1C). Using this bioassay, chemerin bioactivity 
progressively increased after zymosan injection peaking at 8 h 
and decreasing to baseline levels by 96  h (Figure  1C). These 
data suggest that although total chemerin levels as measured 
by ELISA peaked at 4 h and decreased rapidly by 8 h, chemerin 
bioactivity continued to increase up to 8  h and remained 
increased up to 72 h post zymosan injection.
The function of CCRL2 during inflammation remains to be 
fully elucidated, but the expression of CCRL2 has been reported 
to be increased during inflammation (39). To confirm and 
extend this observation, we FACS sorted resident peritoneal 
macrophages as well as recruited peritoneal neutrophils and 
monocytes from wild-type (WT) C57BL/6J mice following a 4 h 
zymosan challenge. We found that Ccrl2 was expressed on three 
cell types but expression was highest on recruited neutrophils 
following zymosan challenge (Figure 1D). In addition, we cul-
tured BMDMs and HUVECs and challenged them with a range 
of inflammatory stimuli (Figures  1E,F). Addition of zymosan, 
LPS, interferon-γ, poly I:C all increased BMDM expression of 
Ccrl2 with the combination of LPS and interferon-γ resulting in 
the largest increase in expression (~235-fold increase compared 
with vehicle) (Figure 1E). Zymosan and LPS also increased Ccrl2 
expression in HUVECs (Figure 1F). These results are in agree-
ment with the published literature, indicating that Ccrl2 expres-
sion is indeed rapidly upregulated on a number of cells during 
acute inflammation (39, 40).
Ccrl2−/− Mice Displayed increased 
Monocyte and neutrophil recruitment to 
the inflamed Peritoneum
To investigate the potential functional consequence of upregula-
tion of CCRL2 during acute inflammation in vivo, we challenged 
WT mice or Ccrl2−/− mice with 100  µg zymosan for 4  h and 
quantified inflammatory cell recruitment and mobilisation. 
Zymosan challenge resulted in significantly more total cells 
recruited to the peritoneum of Ccrl2−/− mice compared with WT 
after 4 h (Figure 2B). There was also a striking increase in mono-
cyte recruitment (0.4 ±  0.05 ×  106 in Ccrl2−/− mice compared 
with 0.2 ± 0.03 × 106 in WT mice) and neutrophil recruitment 
(6.2 ± 0.52 × 106 in Ccrl2−/− mice compared with 3.1 ± 0.35 × 106 
in WT mice) to the peritoneum of Ccrl2−/− mice (Figures 2A–D). 
FigUre 1 | Chemerin bioactivity and Ccrl2 expression are increased during inflammation. C57BL/6J male mice were injected i.p. with 100 µg zymosan. Animals 
were sacrificed at indicated time points, and peritoneal cavities were lavaged with ice-cold PBS supplemented with 2 mM EDTA. (a) Total neutrophils (black broken 
line) and inflammatory monocytes/macrophages (grey line) at indicated time points. (B) Total chemerin levels from the peritoneal exudate fluid were measured by 
ELISA at the indicated time points. (c) Chemerin bioactivity at the Cmklr1 receptor was measured in the peritoneal exudate fluid using CHO-K1 cells stably 
transfected with murine CMKLR1. CMKLR1 activity was assessed by quantification of β-arrestin recruitment to CMKLR1 as measured by luminescence. Dashed line 
represents background luminance. RLU, relative light units. Error bars represent SEM. n = 4–15 mice per time point and n = 4 independent experiments. Statistical 
significance was assessed using one-way analysis of variance (ANOVA) with Dunnett’s multiple comparison post hoc test. (D) C57BL/6J male mice were injected 
i.p. with 100 µg zymosan, and 4 h later steady state or zymosan challenged mice were sacrificed, and peritoneal cavities were lavaged with ice-cold PBS 
supplemented with 2 mM EDTA. Resident peritoneal macrophages from steady state mice and recruited neutrophils and monocytes were sorted by fluorescence-
activated cell sorting into RLT buffer, and Ccrl2 mRNA expression was assessed by qPCR. Error bars represent SEM of n = 3 mice/group. (e,F) mRNA expression 
of Ccrl2 receptor was analysed by qPCR on bone marrow-derived macrophages (BMDMs) and human umbilical vein endothelial cells (HUVECs) following exposure 
to TLR ligands and cytokines for 16 h. Error bars represent SEM of n = 2 separate experiments. Statistical significance was assessed using one-way ANOVA with 
Dunnett’s multiple comparison post hoc test. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001.
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FigUre 2 | Deletion of Ccrl2 increased neutrophil mobilisation and recruitment to local sites of inflammation. 8- to 10-week-old male Ccrl2−/− or age-matched 
littermate controls were injected with zymosan i.p. (100 µg/animal), and 4 h later, zymosan injected animals or steady state animals were sacrificed. Peritoneal 
cavities were lavaged with 5 ml ice-cold PBS supplemented with 2 mM EDTA. Cells were quantified using counting beads, and cell populations were analysed using 
flow cytometry. (a) Representative flow cytometry plots of the peritoneal cavities of wild-type (WT) and Ccrl2−/− steady state mice or mice challenged with zymosan. 
Monocytes were defined as Ly6B.2 (7/4)hi, Ly6Glo and neutrophils were defined as Ly6B.2 (7/4)hi, Ly6Ghi. WT animals are presented on the left and Ccrl2−/− animals 
are presented on the right. (B–D) Total peritoneal cell counts from steady state animals or from animals 4 h post zymosan challenge. Error bars represent SEM of 
n = 4–13 animals/group and n = 2 independent experiments. (e–g) Blood cell counts in WT and Ccrl2−/− mice. Error bars represent SEM. n = 4–9 animals/group 
and n = 2 independent experiments. (h–J) Quantified bone marrow cells. Error bars represent SEM. n = 4–9 animals/group from n = 2 independent experiments. 
Statistical significance was assessed using a two-way analysis of variance with Dunnett’s post hoc multiple comparisons test *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, 
****P ≤ 0.0001.
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TaBle 1 | Local mediators (pg/ml) produced in peritoneal exudate cell fluid following 4 h challenge with 100 µg zymosan i.p. as measured by Luminex.
il-6 ccl2 ccl3 ccl4 cXcl1 cXcl2 cXcl10
ns ns ns ns ns ns ns
Wild type 759 ± 123 1,218 ± 81 34.50 ± 5.3 744.3 ± 41 78.6 ± 6.4 506 ± 166 620 ± 50
Ccrl2−/− 705 ± 83 1,013 ± 21 26.40 ± 2.1 736.8 ± 32 127.8 ± 28 400 ± 148 525 ± 24
Data are presented as mean ± SEM of n = 8 animals.
Statistical significance was assessed by a Student’s unpaired t-test, ns = P > 0.05.
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Other cell populations including CD4 T cells, CD8 T cells and 
B  cells were also quantified but no significant differences were 
observed between the two genotypes (data not shown).
We next examined the blood from these animals 4  h post 
zymosan challenge to investigate whether the increased mono-
cyte and neutrophil recruitment we observed at the site of 
inflammation was mirrored in the blood, indicating increased 
mobilisation of innate immune cells from bone marrow and 
spleen. Similarly to the peritoneum, there was a twofold increase 
in blood neutrophils in Ccrl2−/− mice challenged with zymosan 
compared with WT (Figure 2E). There was also an increase in 
Ly6Chi monocytes, although this was not significant (Figure 2F). 
In agreement with the results from the peritoneum, there were 
no differences in circulating B cells, CD4 T cells or CD8 T cells 
between these genotypes (data not shown).
Since we observed increased neutrophil and monocyte 
numbers in the peritoneum and blood of Ccrl2−/− mice following 
zymosan challenge, we investigated if the increased numbers of 
systemic leucocytes was associated with differences in levels in 
the bone marrow (Figures 2H–J). Ccrl2−/− did not display any sig-
nificant differences in total bone marrow neutrophils (Figure 2H) 
monocytes (Figure  2I) or B  cells (Figure  2J). Collectively, our 
results suggest that the elevated neutrophil levels observed in the 
peritoneum are the result of increased initial systemic inflamma-
tory responses of Ccrl2−/− mice.
Intriguingly, CCRL2 appears to be primarily important in 
the initial stages of the acute inflammatory response. When we 
investigated later time points following zymosan challenge (48 h), 
we found no significant differences in neutrophil or monocyte 
numbers in the peritoneum or blood between Ccrl2−/− mice 
and WT mice (Figures S2B,C,E,F in Supplementary Material). 
In addition, there were no significant differences in local or 
systemic chemerin levels at this late time point (Figures S2D,G in 
Supplementary Material).
steady state Ccrl2−/− Mice Displayed no 
Obvious alterations in resident leucocyte 
Populations in any Tissues examined
To establish whether the increased inflammatory cell recruit-
ment observed in Ccrl2−/− mice during zymosan challenge could 
be explained by increased circulating myeloid cells under resting 
conditions, we undertook a phenotypic analysis of the perito-
neum, blood, bone marrow and spleen of unchallenged WT and 
Ccrl2−/− mice (Figure 2). We found no differences in neutrophils 
or monocytes between the two groups (Figures 2C,D). There 
were no differences in Ly6Chi monocytes, Ly6Clo monocytes or 
neutrophils in the blood between the two groups (Figures 2E–G). 
Similarly, there were no differences in monocytes, neutrophils 
or B cells in the bone marrow (Figures 2H–J). Nor were there 
obvious differences in the spleens under homeostatic conditions 
(data not shown). Finally, we endeavoured to assay basal levels 
of CXCL1 and IL-6 in the peritoneal lavage fluid of these mice, 
but all samples tested were below the limit of detection (set at 
15 pg/ml) of the assays (data not shown). These results indicate 
that the increased neutrophil and monocyte recruitment to 
the peritoneum seen following zymosan challenge were due 
to differences in initial inflammatory responses rather than a 
constitutive increase in circulating neutrophil and monocyte 
numbers.
Ccrl2−/− Mice Displayed increased cXcl1 
and chemerin levels at early Time Points 
following Zymosan challenge
Having shown that mice lacking the CCRL2 chemerin receptor 
displayed exaggerated acute inflammatory responses following 
zymosan challenge, we next investigated if the increased mono-
cyte and neutrophil recruitment was due to elevated chemokine 
or inflammatory mediator levels. There were no significant dif-
ferences in mediator levels between the two genotypes at the 4 h 
time point (Table 1). However, a number of mediators including 
CXCL1 (an important neutrophil chemoattractant) and IL-6 
displayed rapid induction following zymosan challenge peaking 
at 2 h (Figures 3A,B).
Since CXCL1 and IL-6 levels peaked rapidly following 
zymosan insult, we challenged both Ccrl2−/− mice and littermate 
controls with zymosan for 2 h and assessed the resulting inflam-
matory responses. Similar to the 4  h time point, we observed 
significantly more neutrophils recruited to the peritoneum in 
the Ccrl2−/− mice compared with WT (Figure  3E). There were 
very few if any monocytes recruited to the peritoneum at this 
early time point (Figure  1B). We observed a twofold increase 
in CXCL1 levels in the peritoneum of these animals as well as 
significantly elevated chemerin levels (Figures 3F,G). Whilst we 
observed no obvious differences in monocyte or neutrophil num-
bers in the blood (Figures 2H,I), there was a threefold increase 
in CXCL1 plasma levels (Figure 3K). Chemerin levels were also 
significantly elevated in the blood of the Ccrl2−/− mice compared 
with WT at the 2 h time point (Figure 3L).
Ccrl2−/− Mice Displayed increased 
neutrophil numbers in the Peritoneum 
after Thioglycollate challenge
To explore if the increased neutrophil recruitment observed 
in the Ccrl2−/− mice was also evident with other inflammatory 
FigUre 3 | Increased neutrophil recruitment in Ccrl2−/− mice was associated with increased CXCL1 and chemerin levels at early time points. (a–c) 8- to 
10-week-old male C57BL/6J wild-type (WT) mice were injected with zymosan i.p. (100 µg/animal), and animals were sacrificed at indicated time points. Peritoneal 
cavities were lavaged with ice-cold PBS supplemented with 2 mM EDTA. Mediator levels were quantified by ELISA. Error bars represent SEM. n = 4–15 mice per 
time point and n = 2 independent experiments. Statistical significance was assessed using one-way analysis of variance with Dunnett’s multiple comparisons 
post hoc test. (D–l) 8- to 10-week-old male Ccrl2−/− or age-matched littermate control mice were injected with zymosan i.p. (100 µg/animal), and animals were 
sacrificed 2 h later. Cells were quantified using counting beads, and cell populations were analysed using flow cytometry. (D,e) Total peritoneal cell counts following 
2 h zymosan challenge. (F) CXCL1 and chemerin (g) levels in the peritoneum of Ccrl2−/− and WT mice quantified by ELISA. (h,i) Blood neutrophils and monocytes 
in WT and Ccrl2−/− mice. (J,K) Plasma levels of CXCL1 and chemerin quantified by ELISA. Data are presented as mean ± SEM. n = 8 animals/group and n = 2 
independent experiments. Statistical significance was assessed using a Student’s unpaired t-test. *P ≤ 0.05, **P ≤ 0.01.
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stimuli, we challenged these mice i.p. with thioglycollate. 
Thioglycollate is a well-established inflammatory stimulus 
used to elicit inflammatory macrophages (after 4–5 days) (45, 
52). However, it can also be used to interrogate neutrophil 
recruitment in the initial stages of inflammation. Following a 
1 h challenge with 4% thioglycollate, we observed a small but 
distinct population of neutrophils recruited to the peritoneum 
(Figure  4A). We chose this time point because it represents 
an early stage of neutrophil recruitment in response to 
thioglycollate. Ccrl2−/− mice displayed a twofold increase in 
neutrophil recruitment to the peritoneum compared with WT 
controls (0.07 ± 0.01 × 106 neutrophils in WT compared with 
0.13 ±  0.01 ×  106 neutrophils in Ccrl2−/− mice) (Figure  4C). 
There were also significantly higher CXCL1 and chemerin levels 
in the peritoneum of the Ccrl2−/− mice compared with WT mice 
at this early time point (Figures 4D,E).
When we examined the blood of these mice, there was no 
difference in neutrophil numbers between Ccrl2−/− mice and 
FigUre 4 | Mice lacking Ccrl2 displayed exaggerated neutrophil recruitment during acute inflammation independently of stimulus. 8- to 10-week-old male 
Ccrl2−/− mice or age-matched littermate controls were injected with 4% thioglycollate, and 1 h later, animals were sacrificed. Peritoneal cavities were lavaged with 
ice-cold PBS supplemented with 2 mM EDTA. Cells were quantified using counting beads, and cell populations were analysed using flow cytometry. (a) 
Representative flow cytometry plots of the peritoneal cavities of wild-type (WT) and Ccrl2−/− mice treated with thioglycollate. Neutrophils were defined as Ly6B.2 
(7/4)hi and Ly6Ghi (B,c) Total peritoneal cell counts following 1-h thioglycollate challenge. (D) CXCL1 and chemerin (e) levels in the peritoneum of Ccrl2−/− and WT 
mice quantified by ELISA. Total blood leucocytes (F) and neutrophils (g) in WT and Ccrl2−/− mice. (h) Plasma CXCL1 and chemerin (i) levels in Ccrl2−/− and WT 
quantified by ELISA. Mean ± SEM. n = 5 animals/group and n = 1 experiment. Statistical significance was assessed using a Student’s unpaired t-test. *P ≤ 0.05.
9
Regan-Komito et al. CCRL2 Regulates Acute Inflammation
Frontiers in Immunology | www.frontiersin.org November 2017 | Volume 8 | Article 1621
WT controls (Figures  4F,G). This is perhaps not surprising 
given the early time point tested. There were, however, elevated 
chemerin levels in the blood of the Ccrl2−/− mice compared with 
WT controls (Figure 4I). As we did not observe any differences 
in neutrophil numbers in the blood of these animals, it seems 
unlikely there would be changes in the bone marrow at this early 
time point but this was not assessed (53). Collectively, these 
observations demonstrate that mice lacking Ccrl2 display exag-
gerated neutrophil recruitment to local sites of inflammation as 
well as elevated chemerin and CXCL1 levels irrespective of the 
stimulus used to elicit the response.
neutralisation of endogenous chemerin in 
Ccrl2−/− Mice abrogated the exaggerated 
inflammatory Phenotype
From our previous experiments, Ccrl2−/− mice displayed 
increased myeloid cell recruitment in short-term models of acute 
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inflammation. This was associated with elevated CXCL1 and 
chemerin levels. Given our group and others have identified the 
CCRL2 ligand chemerin, as an important modulator of inflam-
mation and chemotaxis, it seemed plausible that the elevated 
levels of chemerin during acute inflammation in Ccrl2−/− mice 
was responsible for the increased myeloid cell recruitment 
(20, 21, 23). To test this hypothesis, we used a blocking anti-
chemerin antibody to neutralise endogenous chemerin levels in 
the Ccrl2−/− mice before zymosan challenge (Figure 5). We first 
confirmed that this antibody could indeed block signalling at the 
CMKLR1 receptor. Using CMKLR1 transfected CHO-K1 cells, 
we demonstrated that preincubation with the antibody efficiently 
blocked chemerin induced β-arrestin recruitment to CMKLR1 
(Figure  5A). We also tested the antibody in primary cells and 
confirmed that it effectively blocked chemerin-induced chemo-
taxis of biogel-elicited macrophages in a real-time chemotaxis 
system (Figure 5B). Following a 24 h pretreatment with isotype 
control or anti-chemerin antibody, Ccrl2−/− mice were challenged 
for 4 h with zymosan as before (Figure 5C). Animals that received 
the anti-chemerin antibody displayed significantly less total leu-
cocyte and neutrophil recruitment to the peritoneum compared 
with mice that received the isotype control (Figures 5D,E; Figure 
S1 in Supplementary Material). There was no significant effect on 
monocyte recruitment (Figure 5F). When we measured mediator 
levels in the peritoneum of these mice, we observed a twofold 
reduction in CXCL1 levels in the anti-chemerin treated mice 
compared with isotype control treated mice and no differences 
in IL-6 levels between the groups (Figures 5G,H). These results 
indicate that the elevated chemerin levels observed in Ccrl2−/− 
mice contribute to the exaggerated leucocyte recruitment as well 
as the elevated CXCL1 levels observed in these mice during acute 
inflammation.
chemerin, the ligand for ccrl2, increased 
neutrophil recruitment in WT Mice
Chemerin has previously been reported to induce the expression 
of various inflammatory cytokines and chemokines (includ-
ing CXCL1 and CCL2) in epithelial and endothelial cells (54, 
55). This provides a possible mechanism by which the higher 
chemerin levels in Ccrl2−/− mice could cause increased CXCL1 
levels during an inflammatory response. To further investigate 
the role of chemerin in exacerbating inflammation in our model, 
we pretreated WT mice with recombinant murine chemerin 
(4 µg/mouse) for 1 h before zymosan challenge (Figures 6A,B). 
Mice that received chemerin pretreatment displayed increased 
total cell recruitment to the peritoneum compared with mice 
that received PBS (4.5 × 106 leucocytes in PBS treated animals 
compared with 7.5 ×  106 leucocytes in chemerin pretreated) 
(Figure 6C). Chemerin pretreated mice also displayed increased 
neutrophil recruitment to the peritoneum compared with 
PBS pretreated mice (2.5 ±  0.5 ×  106 neutrophils in zymosan 
alone compared with 4.5 ±  0.7 ×  106 in chemerin pretreated) 
(Figure 6D). We did not observe any differences in monocyte 
recruitment between the groups (Figure  6E). Importantly, 
injection of chemerin alone did not result in any neutrophil or 
monocyte recruitment (Figures 6B–E). When we analysed the 
inflammatory exudate from these mice, we found that chemerin 
pretreated mice had significantly higher levels of CXCL1 and 
IL-6 (Figures 6F,G). Mice that were treated with chemerin dis-
played a 2-fold and 2.6-fold increase in CXCL1 and IL-6 levels, 
respectively. We also observed similar effects using a lower dose 
of 0.5 µg chemerin per mouse as a pretreatment before zymosan 
challenge (data not shown).
increased recruitment of neutrophils and 
Monocytes in Ccrl2−/− Mice Was not due 
to a Direct effect of ccrl2 on chemerin 
induced chemotaxis
One possible explanation for the observed differences in inflam-
matory cell recruitment was that lack of CCRL2 may in someway 
alter the migratory behaviour of inflammatory cells in response to 
chemerin or other chemotactic ligands. To test this, we used Bio-
gel elicited PECs, which we recently demonstrated to be a mixture 
of inflammatory macrophages and neutrophils (50, 51). We first 
demonstrated that Bio-gel elicited neutrophils do not express the 
chemerin CMKLR1 receptor (Figure  7A). Using the real-time 
chemotaxis platform, we demonstrated that deletion of CCRL2 
had no appreciable effect on PEC migration towards chemerin, 
CCL5, CXCL1, or C5a, ruling out any direct effect of CCRL2 on 
cell migration (Figures 7B–E).
DiscUssiOn
In this study, we have demonstrated for the first time that CCRL2 
plays a non-redundant role in dampening the recruitment of 
myeloid cells to local sites of acute inflammation. We report that 
CCRL2 is expressed on resident peritoneal macrophages as well 
as recruited monocytes and neutrophils following zymosan chal-
lenge (Figure 1D). Interestingly, the highest levels of expression 
appear to be on recruited neutrophils and this is in agreement 
with a recent report by Del Prete et al. (56). In addition, Ccrl2 
expression on macrophages and endothelial cells is increased 
after exposure to inflammatory stimuli. This is in agreement with 
published reports (Figures 1E,F) (39, 40). After 4 h of zymosan 
challenge we observed that mice lacking expression of the CCRL2 
chemerin receptor displayed a twofold increase in monocyte 
and neutrophil recruitment to the peritoneum (Figures 2B,C). 
These effects of CCRL2 were not localised only to the site of 
inflammation, as we also observed increased neutrophil num-
bers in the blood, suggesting more systemic effect (Figure 2E). 
These systemic effects were predominantly associated with 
neutrophil recruitment as we did not observe significant dif-
ferences in monocyte numbers in the blood or bone marrow 
(Figures  2F,I). The fact that there were significant differences 
only in local monocyte numbers but not in systemic numbers 
may be a feature of the early time point evaluated here, as we 
know from our kinetic studies that monocyte numbers peak later 
(Figure 1B). Importantly, at an earlier time point (2 h) in which 
we could more easily evaluate cytokine and chemokine levels, 
we observed that mice lacking CCRL2 displayed higher levels 
of CXCL1 in the peritoneum (Figure  3F). The elevated levels 
of CXCL1 both locally and systemically would explain why the 
majority of differences we observe in the Ccrl2−/− mice were in the 
FigUre 5 | Treatment with an anti-chemerin blocking antibody attenuated the exaggerated inflammatory responses observed in Ccrl2−/− mice. (a) CHO-K1 cells 
stably transfected with murine CMKLR1 were plated out in a 96-well plate for 48 h before stimulation. Cells were challenged with indicated concentrations of 
anti-chemerin antibody or isotype control before challenge with 20 nM murine chemerin. Cmklr1 activity was assessed by quantification of β-arrestin recruitment to 
CMKLR1 as measured by luminescence. RLU, relative light units. Error bars = SD of three technical replicates of one experiment. (B) Representative real-time 
chemotaxis trace of biogel-elicited peritoneal exudate cells (PECs). 8- to 10-week-old male C57BL/6J mice were injected i.p. with 2% Bio-gel (polyacrylamide 
beads) and sacrificed 4 days later. Peritoneal cavities were lavaged with ice-cold PBS supplemented with 2 mM EDTA. Cells were pretreated with vehicle or 
anti-chemerin antibody (ab) for 45 min. A gradient of 5 nM of the 5 nM chemerin was allowed to form, and chemotaxis was measured of 4 × 105 cells 
(400,000 cells/well) for 3 h. (c) Schematic of in vivo experimental design. (D–g) 8- to 10-week-old male Ccrl2−/− mice were pretreated with 100 ng of anti-chemerin 
blocking antibody or isotype control IgG antibody i.p. for 24 h before challenge with zymosan for 4 h. Animals were sacrificed, and peritoneal cavities were lavaged 
with ice-cold PBS supplemented with 2 mM EDTA. Cells were quantified using counting beads, and cell populations were analysed using flow cytometry (D) Total 
cells. (e) Total neutrophils. (F). Total monocytes. Levels of CXCL1 (g) and IL-6 (h) in the peritoneum of indicated groups were quantified by ELISA. Mean ± SEM. 
n = 2–8 mice/group. Statistical significance was assessed using a Student’s unpaired t-test. *P ≤ 0.05, **P ≤ 0.01.
11
Regan-Komito et al. CCRL2 Regulates Acute Inflammation
Frontiers in Immunology | www.frontiersin.org November 2017 | Volume 8 | Article 1621
context of neutrophil migration. This phenotype was consistently 
associated with higher endogenous levels of chemerin in Ccrl2−/− 
mice and was abrogated after blocking chemerin activity with an 
anti-chemerin antibody (Figure 5). Furthermore, this phenotype 
was recapitulated in WT mice by injection of recombinant murine 
chemerin, further indicating a role for chemerin in driving this 
FigUre 6 | Recombinant chemerin pretreatment increased inflammatory cell recruitment in mice during acute inflammation. (a) 8- to 10-week-old male C57BL/6J 
mice were pretreated (i.p.) with recombinant murine chemerin (4 µg/mouse) or PBS for 1 h before challenge with zymosan i.p. (100 μg/mouse). 4 h later, mice were 
sacrificed, and peritoneal cavities were lavaged with ice-cold PBS supplemented with 2 mM EDTA. Cells were quantified using counting beads, and cell populations 
were analysed using flow cytometry. (B) Representative flow cytometry plots of the peritoneal cavities of wild-type and Ccrl2−/− mice challenged with indicated 
treatments. Monocytes were defined as Ly6B.2 (7/4)hi, Ly6Glo and neutrophils were defined as Ly6B.2 (7/4)hi, Ly6Ghi. (c) Total CD45+ leucocytes recruited to the 
peritoneum of indicated groups following zymosan challenge. (D) Total neutrophils recruited to the peritoneum of indicated groups following zymosan challenge.  
(e) Total monocytes recruited to the peritoneum of indicated groups following zymosan challenge. Error bars represent SEM. n = 3–7 mice/group and n = 2 
independent experiments. Levels of CXCL1 (F) and IL-6 (g) in the peritoneum of indicated groups. Mean ± SEM. n = 6–7 mice/group. Statistical significance was 
assessed using a Student’s unpaired t-test. *P ≤ 0.05, **P ≤ 0.01.
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exaggerated neutrophil recruitment (Figure  6). Finally, this 
exaggerated inflammatory phenotype of Ccrl2−/− mice appears 
to be predominantly associated with the initial stages of acute 
inflammatory responses. Absence of CCRL2 did not appear to 
affect neutrophil or monocyte numbers locally or systemically at 
later time points (Figure S2 in Supplementary Material).
CCRL2 is one of the less studied chemerin receptors and 
arguably performs the least obvious function. It binds chemerin 
FigUre 7 | Absence of Ccrl2 had no effect on the migratory behaviour of leucocytes towards macrophage or neutrophil chemoattractants. 8- to 10-week-old male 
Ccrl2−/− mice and age-matched littermate controls were injected i.p. with 2% Bio-gel (polyacrylamide beads) and sacrificed 4 days later. Peritoneal cavities were 
lavaged with ice-cold PBS supplemented with 2 mM EDTA. (a) Representative histogram cytometry plots displaying CMKLR1 expression on biogel elicited 
macrophages and neutrophils. Macrophages were defined as F4/80hi, Ly6B.2 (7/4)lo, Ly6Glo, neutrophils were defined as Ly6B.2 (7/4)hi, Ly6Ghi. (B,e) A gradient of 
5 nM of the indicated chemoattractant was allowed to form, and chemotaxis was measured of 4 × 105 cells (400,000 cells/well) for 3 h. Representative chemotaxis 
traces of wild type and Ccrl2−/− peritoneal exudate cell chemotaxis to 5 nM chemerin (B) or 5 nM C5a. (c). (D) Max–Min analysis and (e) slope analysis. Error bars 
are SEM of four experiments with independent macrophage preparations. Significance was assessed using two-way analysis of variance with Sidak’s multiple 
comparison test. ns = P > 0.05.
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but there is no reported downstream signalling upon receptor 
ligation in primary cells (38, 39). Whilst it was initially thought 
to serve a similar function to the decoy receptors ACKR1 (or 
DARC) and ACKR2 (or D6), which dampen inflammation by 
binding and internalising inflammatory chemokines, CCRL2 
does not internalise chemerin or any other chemokines 
(38, 57). Whilst the exact role of CCRL2 during inflammation 
has yet to be fully elucidated, its expression has been documented 
by a number of groups including in this report (Figures 1E,F) 
to be rapidly upregulated during inflammation, suggesting a 
conserved function required during inflammatory responses 
(39, 40).
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Several studies have endeavoured to clarify the role played 
by CCRL2 in vivo but there have been conflicting results in dif-
ferent experimental models. Zabel et al. demonstrated that mice 
lacking CCRL2 displayed reduced ear swelling and leucocyte 
influx in a mast cell dependent model of atopic allergy. The 
exact mechanism by which CCRL2 modulated these responses 
was not clear. However, cells expressing CCRL2 were shown 
to bind and concentrate chemerin locally in  vitro. When these 
cells were incubated with Cmklr1 transfected cells, they induced 
calcium flux, indicating a possible role for CCRL2 in chemerin 
presentation (38). In the in vitro model, CCRL2 expressing cells 
were capable of binding chemerin and presenting it to CMKLR1 
expressing cells when in close proximity. It was postulated this 
mode of action played a role in mast cell responses to low dose 
IgE challenge. However, this seems unlikely to be the case in our 
model of acute inflammation. Administration of recombinant 
bioactive chemerin to WT mice exacerbated the acute inflamma-
tory response (Figure 6). If CCRL2 were functioning to increase 
chemerin signalling, which appears to be pro-inflammatory here, 
one would expect to observe reduced inflammation following 
zymosan challenge in Ccrl2−/− mice. Yet in Figures 2 and 3, we 
observed the converse. An alternative hypothesis, therefore, is 
that in vivo, increased expression of CCRL2 on other cell types 
during inflammation such as vascular endothelial cells may 
enable binding of free chemerin, which in turn reduces systemic 
levels of chemerin (39). This would thereby decrease the chemerin 
available to interact with CMKLR1 expressing cells and therefore 
dampen the ensuing pro-inflammatory responses elicited by 
chemerin as described by Neves et al. (55).
Mazzon et  al. reported that mice lacking CCRL2 displayed 
exacerbated disease in a model of experimental autoimmune 
encephalitis (EAE) as well as increased Ccrl2 expression on 
mononuclear cells in WT mice during EAE (58). The authors 
reported that in mice lacking CCRL2, T cells, and macrophages 
were further polarised towards an inflammatory phenotype dur-
ing disease, but the mechanism by which deletion of the Ccrl2 
gene enhanced disease remained unexplained (58).
At the time of writing, the same group more recently reported 
a new study in which mice lacking CCRL2 were protected in two 
murine models of arthritis in contrast to their previous study using 
the EAE model, highlighting the complexity of the chemerin/
CCRL2 axis (56, 58). Importantly, the authors report that the 
protective effect of deletion of Ccrl2 in these models was due to 
defects in neutrophil recruitment and trafficking due to CXCR2 
heterodimersastion with CCRL2. These results seem to be at odds 
with our current findings but possibly reflect differences in the 
disease models used to interrogate this biology. The kinetics and 
disease pathology differ significantly between the acute models 
of inflammation used in our study and the more chronic disease 
models used by Del Prete et al. in their most recent report (56). 
Clearly, further studies will be necessary to clarify the exact role 
played by CCRL2 during inflammation but it seems likely to be 
disease and even tissue specific (59).
In agreement with an earlier study by Monnier et  al. who 
reported higher chemerin levels in the blood of Ccrl2−/− mice 
following intranasal administration of LPS, we observed elevated 
chemerin levels in the blood of Ccrl2−/− animals following 
zymosan and thioglycollate challenge (Figures 3 and 4) (39). In 
addition, using BMDMs from WT animals and HUVECs, we 
observed increased expression of Ccrl2 mRNA after stimulation 
with inflammatory stimuli (up to ~230-fold increase on BMDMs) 
(Figure 1E). We also report increased neutrophil recruitment and 
CXCL1 levels both locally and systemically (Figures 2 and 3) in 
Ccrl2−/− mice challenged with 100 µg zymosan. To the best of our 
knowledge, this is the first report of such an observation. The 
increased neutrophil recruitment during acute inflammation in 
these mice can be at least partly explained by increased CXCL1 
and chemerin levels. Previous studies from our lab and others 
have not detected the chemotactic chemerin receptor CMKLR1 
on murine neutrophils (23, 56, 60). There has since been one 
report of murine neutrophils expressing CMKLR1; however, we 
failed to detect any CMKLR1 expression on murine neutrophils 
(Figure 7A) (35). It seems unlikely, therefore, that the increased 
neutrophil recruitment we observed in our model is due to 
any direct chemotactic effects of chemerin on neutrophils. We 
did not observe any differences in migration between WT and 
Ccrl2−/− cells in response any mediators tested in agreement with 
Del Prete et al. (Figures 7C,D) (56). Importantly, the phenotype 
observed in Ccrl2−/− mice is not related to the receptors that detect 
zymosan (dectin-1, TLR2/6) as we observed a similar phenotype 
with thioglycollate challenge, which is a more severe inflamma-
tory insult (61). Our results support the hypothesis that CCRL2 is 
important for regulating both local and systemic chemerin levels 
during an acute inflammatory response.
This exacerbated inflammatory response was not simply a 
feature of increased basal myeloid cell numbers, as we observed 
no differences in leucocyte populations between the two groups 
in any tissue tested under steady state conditions (Figure  2). 
Rather, the increased myeloid cell recruitment in Ccrl2−/− mice 
was associated with increased chemerin and CXCL1 levels 
both locally and systemically. Chemerin has previously been 
reported to induce pro-inflammatory signalling in microvascular 
endothelial and smooth muscle cells (55). Chemerin treatment 
increased mRNA expression of a number of pro-inflammatory 
mediators including CCL2, TNF-α, and VCAM-1 (55). Another 
study by Lin et  al. demonstrated that chemerin administration 
to WT mice induced more severe inflammation in a model of 
DSS-induced colitis, which was characterised by increased 
inflammatory cytokines and an inhibition of M2 polarisation of 
resident macrophages (62). Taken together, these reports support 
our hypothesis that increased chemerin levels observed in the 
Ccrl2−/− mice were responsible for increased myeloid cell recruit-
ment via the increased production of inflammatory mediators 
such as CXCL1 during sterile peritonitis.
We confirmed the importance of chemerin in the phenotype 
of Ccrl2−/− mice using an anti-chemerin polyclonal blocking 
antibody to inhibit chemerin signalling in these animals before 
zymosan challenge (Figure  5). Neutralisation of endogenous 
chemerin in the Ccrl2−/− mice decreased the total leucocytes 
and neutrophils recruited to the peritoneum compared with 
isotype controls, indicating that elevated chemerin levels did 
indeed play a role in the exaggerated neutrophil recruitment 
observed in these animals (Figures  5C,D). We previously 
observed that blockade of endogenous chemerin in WT mice 
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resulted in increased neutrophil and monocyte recruitment 
to the peritoneum of WT mice following challenge with 10 µg 
zymosan (34). In our current study, we did not interrogate 
chemerin blockade in WT mice but when chemerin activity was 
blocked in Ccrl2−/− mice during 100 µg zymosan challenge, we 
observed decreased neutrophil recruitment compared with iso-
type control treated Ccrl2−/− mice. These data highlight further 
differences in chemerin behaviour depending on the intensity 
of inflammatory insult and genetic backgrounds used. From 
the results in our current study, it is plausible that chemerin 
may be more important for driving neutrophil rather than 
monocyte recruitment in this acute model of inflammation, 
as chemerin blockade had no significant effect on monocyte 
numbers. However, it is known that neutrophils are important 
for the recruitment of monocytes during an inflammatory 
response and are capable of secreting a number of monocyte 
chemoattractants (63, 64). Chemerin bioactivity may not have 
been completely blocked in these animals, hence although we 
observed a significant decrease in neutrophil recruitment, this 
may not been sufficiently blunted to in turn appreciably decrease 
monocyte recruitment at this time point. When we interrogated 
mediator levels, we observed a significant decrease in local 
levels of CXCL1 but no change in IL-6 following blockade of 
endogenous chemerin (Figures  5F,G). CXCL1 and IL-6 were 
evaluated as CXCL1 is a key driver of neutrophil recruitment 
and IL-6 is a systemic marker of inflammation (65–68).
As predicted from our results using chemerin blocking 
antibodies, chemerin pretreatment of WT mice before zymosan 
challenge increased total cell and neutrophil recruitment to the 
peritoneum as well as elevated levels of inflammatory chemokines 
and cytokines, similar to what we observed in the Ccrl2−/− mice 
(Figure  6). Importantly, injection of chemerin alone did not 
induce any neutrophil recruitment after 4  h at the dose used 
(Figures 6B–E). We demonstrate here that full-length bioactive 
chemerin can increase neutrophil recruitment when admin-
istered before an inflammatory stimulus but previous studies 
from our laboratory have reported that a synthetic chemerin-
derived peptide called C15 has anti-inflammatory effects in a 
similar model (albeit using 10-fold lower dose of zymosan as 
an inflammatory stimulus) (34). The most likely explanation for 
this apparent discrepancy is differences in the pharmacology 
and downstream signalling between the full-length chemerin 
protein and the 15 amino acid chemerin peptide. The signalling 
cascades that are activated at the murine CMKLR1 receptor 
upon chemerin binding for example, are relatively well charac-
terised (involving the MAP kinase, RhoA, ROCK, MEK1/2, and 
P38 proteins amongst others) (23, 26). However, very little if 
anything is known about the signalling pathways induced by the 
C15 peptide. Whilst chemerin is known to act as a potent che-
moattactant for macrophages, DCs, and NK cells, C15 does not 
exhibit similar effects on any cell types investigated thus far (20, 
22, 23, 30, 50). Clearly, the full-length protein and the smaller 
peptide elicit quite different intracellular signalling pathways 
downstream of the CMKLR1 chemerin receptor and this would 
suggest they play quite different roles in vivo.
We have endeavoured to confirm the requirement for CXCL1 
in the exaggerated neutrophil recruitment in Ccrl2−/− mice by 
pretreating WT and Ccrl2−/− mice with a blocking anti-CXCL1 
antibody before zymosan challenge. However, we did not observe 
significant decreases in neutrophil recruitment in either group 
despite previous reports (data not shown) (65). However, these 
results are perhaps not surprising given the high affinity of these 
chemokines for their receptors as well as the functional redun-
dancy in the system (69). Hence, we have demonstrated that 
chemerin is elevated in Ccrl2−/− mice and that elevated chemerin 
is capable of driving the exaggerated neutrophil recruitment and 
increased levels of CXCL1 during acute inflammation. However, 
we cannot exclude the possibility that other mediators or path-
ways are also involved. Further studies will be required to fully 
clarify this.
In summary, we have demonstrated that the non-signalling 
chemerin receptor CCRL2 serves a non-redundant role in 
dampening acute inflammatory responses in vivo. The absence 
of CCRL2 resulted in exaggerated acute inflammatory responses 
as well as elevated CXCL1 and chemerin levels. Blockade of 
endogenous chemerin in Ccrl2−/− mice abrogated the elevated 
neutrophil recruitment. We observed that administration of 
recombinant murine chemerin to WT mice induced similar exag-
gerated inflammatory responses to those seen in Ccrl2−/− mice. 
Importantly, deletion of the Ccrl2 gene did not have any direct 
effect on myeloid cell chemotaxis towards chemerin or other 
chemokines. Our data are consistent with a model in which 
CCRL2 serves to bind and maintain chemerin levels below a 
pathological threshold during acute inflammation and the more 
severe inflammatory responses observed in Ccrl2−/− mice are 
due to significantly elevated free chemerin levels. The increased 
chemerin signalling in turn induces higher production of inflam-
matory chemokines such as CXCL1, which results in elevated 
myeloid cell recruitment and more severe inflammation. Our 
experiments suggest that chemerin could be a therapeutic target 
in the treatment of inflammatory diseases, particularly RA, in 
which chemerin has consistently been implicated in the pathol-
ogy of this disease (16, 19, 54, 70).
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